Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.
Selected pharmacological interventions may improve body composition outcomes in acquired hypothalamic obesity, but the evidence is limited and of low certainty.
Where it sits
this study against the rest of the exenatide corpusSummary and findings
This systematic review evaluated the effects of pharmacological interventions on body composition outcomes and lifestyle interventions in patients with acquired hypothalamic obesity. Seven randomized controlled trials were included, with findings indicating that long-acting exenatide reduced fat mass without substantial lean mass loss. The overall evidence remains limited and of low certainty.
Abstract
<h4>Objective</h4>This review aimed to systematically evaluate the effects of pharmacological interventions on body composition outcomes and lifestyle intervention as background therapy in patients with acquired hypothalamic obesity (aHO).<h4>Methods</h4>Searches were conducted in PubMed, Embase, the Cochrane Library, CINAHL, and CNKI for studies published between July 24, 2015, and November 8, 2025. Eligible studies were full-text randomized controlled trials (RCTs) evaluating pharmacological and/or lifestyle weight management interventions in patients with aHO of any age. Outcomes included four domains: anthropometric and body composition measures, metabolic markers, behavioral and energy-related outcomes, and adverse events. Risk of bias was assessed using the adapted Cochrane Risk of Bias Tool, and certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Owing to substantial heterogeneity in interventions and outcome measurements, only descriptive synthesis was performed.<h4>Results</h4>Seven RCTs were included. Semaglutide demonstrated sustained weight loss, while long-acting exenatide reduced fat mass without substantial lean mass loss. Tesomet was associated with reductions in both body weight and lean mass, whereas diazoxide showed limited efficacy for weight management. Several interventions improved satiety and reduced hunger, although metabolic findings were inconsistent across studies. Adverse events were mostly mild to moderate. Risk of bias assessment identified one study at high risk of bias and one with some concerns. According to the GRADE framework, certainty of evidence was low for anthropometric/body composition, metabolic, and behavioral/energy outcomes and moderate for adverse events.<h4>Conclusions</h4>Current evidence suggests that selected pharmacological interventions may improve weight-related and body composition outcomes in aHO; however, evidence remains limited and of predominantly low certainty. Existing studies are constrained by inadequate assessment of lean body mass and poorly standardized lifestyle interventions. Future large-scale, long-term RCTs incorporating systematic body composition assessment and structured lifestyle intervention protocols are needed.
Background
This review addresses the effects of pharmacological and lifestyle interventions on body composition in patients with acquired hypothalamic obesity (aHO). Prior knowledge indicated that pharmacological treatments could influence weight management, but the specific impacts on body composition were unclear. This study matters as it synthesizes existing randomized controlled trials to evaluate the effectiveness of these interventions.
Methods
The study design involved a systematic review of randomized controlled trials published between July 24, 2015, and November 8, 2025. Eligible studies included patients with aHO of any age and evaluated pharmacological and/or lifestyle weight management interventions. The review focused on anthropometric and body composition measures, metabolic markers, behavioral and energy-related outcomes, and adverse events.
Results
The review included seven RCTs. Long-acting exenatide was noted to reduce fat mass without substantial lean mass loss. Semaglutide was associated with sustained weight loss, while tesomet showed reductions in both body weight and lean mass. Adverse events reported were mostly mild to moderate, and the certainty of evidence for various outcomes was assessed as low or moderate.
Interpretation
The findings suggest that while some pharmacological interventions may improve body composition outcomes in aHO, the clinical significance of these results is uncertain due to the low certainty of evidence. The small sample sizes and variability in interventions limit the conclusions that can be drawn. This indicates a need for further research to clarify the effectiveness of these treatments in clinical practice.
Key findings
- Seven RCTs included.
- Semaglutide demonstrated sustained weight loss.
- Long-acting exenatide reduced fat mass without substantial lean mass loss.
- Tesomet was associated with reductions in both body weight and lean mass.
- Adverse events were mostly mild to moderate.
- Certainty of evidence was low for anthropometric/body composition, metabolic, and behavioral/energy outcomes.
Limitations
- Only seven RCTs included.
- Low certainty of evidence for most outcomes.
- Inadequate assessment of lean body mass.
- Poorly standardized lifestyle interventions.
- One study at high risk of bias.